Nabriva Therapeutics PLC expected to post a loss of 24 cents a share - Earnings Preview

Nabriva Therapeutics

02/11/2021 02:10

* Nabriva Therapeutics PLC  NBRV.OQ   NBRV.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 3 (estimated). 
* The Dublin, Ireland; Republic of-based company is expected to
report  a 635.9% increase in revenue to $9.5 million from $1.29
million a year ago, according to the estimate from one analyst,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Nabriva Therapeutics
PLC is for a loss of 24 cents per share. For the same quarter
last year, the company reported a loss of 90 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $2.68​, about 54.8% above​ its last closing
price of $1.21. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.32       -0.35      -0.29     Beat    16.3
 Mar. 312021   -0.67       -0.67      -0.53     Beat    20.9
 Dec. 312020               -0.95      -1.11     Missed  -16.8​
 Sep. 302020   -0.90       -0.97      -0.90     Beat    7.7
 ​​Jun.        -1.61       -1.60      -1.40     Beat    12.5
 302020                                                 
 Mar. 312020   -2.69       -2.64      -2.50     Beat    5.3​
 Dec. 312019   -3.24       -3.32      -2.90     Beat    12.7
 Sep. 302019   -2.82       -2.82      -2.40     Beat    15
 This summary was machine generated November 2 at 02:10 GMT.  All
figures in US dollars unless otherwise stated